Study shows how cholesterol becomes dysregulated in brain cancer cells and reports the gene responsible for the dysregulation could be a potential target to help treat glioblastoma brain cancer.
Medications commonly used to treat non-small cell lung cancer that has metastasized may have therapeutic benefits for patients with metastatic brain cancers.
Study finds significant expression of the Alzheimer's related Tau protein in glioma cells, especially in patients with better prognoses.
Extra DNA is critical for maintaining cancer-causing gene activation and supporting the cancer cell's ability to survive.
Teriflunomide, a drug commonly used to treat multiple sclerosis, shows promise for the treatment of glioblastoma when coupled with targeted cancer therapies.
Genetics and microenvironment influence the frequency of glioblastoma cells. Researchers provide a new blueprint for glioblastoma, integrating the malignant cell programs, cancer cell plasticity, and modulation by genetic drivers. The findings shed light on why this form of cancer is so hard to treat effectively.
A new study in PNAS reports blocking the expression of MDA-9/Syntenin forces glioma stem cells to lose their ability to induce protective autophagy.
NIH researchers have identified a set of genes they believe could explain why some people need more, or less, sleep that others. The findings could help to develop new treatments for a variety of sleep disorders from insomnia to narcolepsy.
Researchers at UT Southwestern report medications used to treat arthritis and lung cancer may help in the battle against glioblastoma.
UCLA researchers report erlotinib, an FDA approved drug, reduces glucose uptake in glioblastoma, effectively cutting off nutrients and energy supply to the tumor.
Based on a large scale meta analysis, researchers report striking differences between children's high grade gliomas, so much so that they could be split into 10 different subtypes based on different characteristics. The findings have important implications for developing new and individualized treatments.
A new Baylor study reveals the CD44s molecule gives glioblastoma brain cancer cells a survival advantage. Removing CD44s from cancer cells and treating with erlotinib helped to promote the death of cancer cells than by just treating the cancer with erlotinib alone, researchers said.
